How the case is coded.
Coding Corner Question: August Coding Challenge
A 43-year-old female established patient diagnosed with rheumatoid arthritis comes to the office for her first infliximab infusion.
The Complexity of Lumbar Spinal Stenosis
Challenges in diagnosis and management.
The State-of-the-Art of Rheumatology Symposium
Experts from across the nation describe the best clinical approaches to rheumatologic disease management.
Minerals, Mud, Martinis, and Methylprednisone
How the practice of rheumatology differs in America and Europe.
Coding Corner: Incident-To
A 65-year-old female Medicare patient with rheumatoid arthritis sees a nonphysician provider for a followup visit.
Systemic Juvenile Idiopathic Arthritis
Changing treatment paradigms in the biologic era
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.